Antiandrogen therapy
AstraZeneca’s Truqap Achieves Phase III Success in Prostate Cancer, Reviving Hopes After Breast Cancer Setback
AstraZeneca, Truqap, prostate cancer, Phase III trial, PTEN-deficient metastatic hormone-sensitive prostate cancer, radiographic progression-free survival (rPFS), abiraterone, androgen deprivation therapy (ADT).
AstraZeneca’s Truqap Achieves Phase 3 Success in Prostate Cancer, Paving Way for Label Expansion
AstraZeneca, Truqap, prostate cancer, Phase 3 trial, CAPItello-281, PTEN-deficient, metastatic hormone-sensitive prostate cancer, radiographic progression-free survival (rPFS), abiraterone, androgen deprivation therapy (ADT)
Bayer Seeks to Broaden Nubeqa’s Use in Prostate Cancer with Chemotherapy-Free Treatment Option
Nubeqa, Bayer, prostate cancer, chemotherapy-free, label expansion, ARANOTE trial, darolutamide, androgen deprivation therapy (ADT), metastatic hormone-sensitive prostate cancer (mHSPC)